Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

Rhea-AI Summary

Gossamer Bio, Inc. (NASDAQ: GOSS) has appointed Bryan Giraudo as Chief Operating Officer, maintaining his role as Chief Financial Officer. He joined Gossamer in May 2018 and has significantly contributed to the company's financial and organizational strength. Giraudo's promotion reflects his expanding leadership role. Before joining Gossamer, he was a Senior Managing Director at SVB Leerink and a Managing Director at Merrill Lynch's Global Healthcare Investment Banking Group. Gossamer Bio focuses on therapeutics in immunology, inflammation, and oncology.

Positive

• Appointment of Bryan Giraudo as COO may enhance leadership stability.
• Strengthened financial foundation under Giraudo's leadership since 2018.

Negative

• Concerns regarding continuity in operations with new dual role for Giraudo.

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer. Mr. Giraudo joined Gossamer in May 2018 as its Chief Financial Officer.

“Bryan has been instrumental in strengthening the financial and organizational foundation of the Company,” said Faheem Hasnain, Chairman, co-founder and CEO of Gossamer Bio. “Since his arrival at Gossamer, his responsibilities have extended far beyond just the finance and accounting groups, and this promotion reflects the management and leadership role that Bryan has already established for himself.”

Prior to joining Gossamer Bio, Mr. Giraudo was a Senior Managing Director at Leerink Partners, now known as SVB Leerink, from 2009 to April 2018. Before joining Leerink, Mr. Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005468/en/

For Investors and Media:

Bryan Giraudo, Chief Operating Officer & Chief Financial Officer

Gossamer Bio Investor Relations

ir@gossamerbio.com

Source: Gossamer Bio, Inc.

FAQ

What is the recent leadership change at Gossamer Bio?

Gossamer Bio appointed Bryan Giraudo as Chief Operating Officer while he continues as Chief Financial Officer.

When was Bryan Giraudo appointed as COO of Gossamer Bio?

Bryan Giraudo was appointed as COO on a date not specified in the press release.

What impact might Bryan Giraudo's promotion have on Gossamer Bio?

His promotion may enhance leadership stability and capitalize on his experience to strengthen company operations.